Study for difficult IgA vasculitis with gut symptoms
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at treatment strategies for children with IgA vasculitis (also called Henoch-Schönlein purpura) when it mainly affects the stomach and intestines and symptoms do not improve with standard steroid dosing. It may help find better ways to control the illness early and prevent serious complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and 16 years old
- Your child has IgA vasculitis (Henoch-Schönlein purpura) with stomach or bowel involvement
- Symptoms started less than 2 months ago
- Your child has not improved enough with a regular dose of prednisolone (under 2 mg/kg/day)
- Your child does NOT have life-threatening infection (like severe sepsis) or serious lung infection
- Your child does NOT have certain other major risks like brain infection, long-term infections (EBV/CMV/TB), or kidney failure needing dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests different medicines to calm active skin vasculitis and prevent flare-ups. It’s for people whose vasculitis mainly affects the skin, not major organs like kidneys or the brain.
This study looks at a blood test done when a child is first diagnosed with IgA vasculitis (also called Henoch-Schönlein purpura) to see if it can predict stomach or intestine problems. It involves one extra blood draw at diagnosis and a follow-up visit a few weeks later.
This trial tests if the drug finerenone can help children with IgA vasculitis (HSP nephritis) who have mild protein in their urine. It aims to protect kidney function without using stronger medications like steroids.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
This observational study follows adults with vasculitis (inflammation of blood vessels) during an active flare or relapse. It aims to better understand how the disease changes over time and may help researchers plan future treatments.
Hear when a new Henoch-Schönlein Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.